View in EDS HTML Full Text PDF Full Text

Objective assessment of the effects of opicapone in Parkinson's disease through kinematic analysis.

Saved in:
Bibliographic Details
Title: Objective assessment of the effects of opicapone in Parkinson's disease through kinematic analysis.
Authors: Bologna, Matteo (AUTHOR), Guerra, Andrea (AUTHOR), Colella, Donato (AUTHOR), Birreci, Daniele (AUTHOR), Costa, Davide (AUTHOR), Cannavacciuolo, Antonio (AUTHOR), Angelini, Luca (AUTHOR), Paparella, Giulia (AUTHOR), Antonini, Angelo (AUTHOR), Berardelli, Alfredo (AUTHOR), Fabbrini, Giovanni (AUTHOR)
Source: Neurological Sciences. May2024, Vol. 45 Issue 5, p2035-2046. 12p.
Subjects: Parkinson's disease, Dopa
Abstract: Background: Opicapone (OPC) is a third-generation, selective peripheral COMT inhibitor that improves peripheral L-DOPA bioavailability and reduces OFF time and end-of-dose motor fluctuations in Parkinson's disease (PD) patients. Objectives: In this study, we objectively assessed the effects of adding OPC to L-DOPA on bradykinesia in PD through kinematic analysis of finger movements. Methods: We enrolled 20 treated patients with PD and motor fluctuations. Patients underwent two experimental sessions (L-DOPA, L-DOPA + OPC), separated by at least 1 week. In each session, patients were clinically evaluated and underwent kinematic movement analysis of repetitive finger movements at four time points: (i) before their usual morning dose of L-DOPA (T0), (ii) 30 min (T1), (iii) 1 h and 30 min (T2), and (iv) 3 h and 30 min after the L-DOPA intake (T3). Results: Movement velocity and amplitude of finger movements were higher in PD patients during the session with OPC compared to the session without OPC at all the time points tested. Importantly, the variability of finger movement velocity and amplitude across T0–T3 was significantly lower in the L-DOPA + OPC than L-DOPA session. Conclusions: This study is the first objective assessment of the effects of adding OPC to L-DOPA on bradykinesia in patients with PD and motor fluctuations. OPC, in addition to the standard dopaminergic therapy, leads to significant improvements in bradykinesia during clinically relevant periods associated with peripheral L-DOPA dynamics, i.e., the OFF state in the morning, delayed-ON, and wearing-OFF periods. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 176627737
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Objective assessment of the effects of opicapone in Parkinson's disease through kinematic analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Bologna%2C+Matteo%22">Bologna, Matteo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Guerra%2C+Andrea%22">Guerra, Andrea</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Colella%2C+Donato%22">Colella, Donato</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Birreci%2C+Daniele%22">Birreci, Daniele</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Costa%2C+Davide%22">Costa, Davide</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cannavacciuolo%2C+Antonio%22">Cannavacciuolo, Antonio</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Angelini%2C+Luca%22">Angelini, Luca</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Paparella%2C+Giulia%22">Paparella, Giulia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Antonini%2C+Angelo%22">Antonini, Angelo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Berardelli%2C+Alfredo%22">Berardelli, Alfredo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fabbrini%2C+Giovanni%22">Fabbrini, Giovanni</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. May2024, Vol. 45 Issue 5, p2035-2046. 12p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Parkinson's+disease%22">Parkinson's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Dopa%22">Dopa</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Opicapone (OPC) is a third-generation, selective peripheral COMT inhibitor that improves peripheral L-DOPA bioavailability and reduces OFF time and end-of-dose motor fluctuations in Parkinson's disease (PD) patients. Objectives: In this study, we objectively assessed the effects of adding OPC to L-DOPA on bradykinesia in PD through kinematic analysis of finger movements. Methods: We enrolled 20 treated patients with PD and motor fluctuations. Patients underwent two experimental sessions (L-DOPA, L-DOPA + OPC), separated by at least 1 week. In each session, patients were clinically evaluated and underwent kinematic movement analysis of repetitive finger movements at four time points: (i) before their usual morning dose of L-DOPA (T0), (ii) 30 min (T1), (iii) 1 h and 30 min (T2), and (iv) 3 h and 30 min after the L-DOPA intake (T3). Results: Movement velocity and amplitude of finger movements were higher in PD patients during the session with OPC compared to the session without OPC at all the time points tested. Importantly, the variability of finger movement velocity and amplitude across T0–T3 was significantly lower in the L-DOPA + OPC than L-DOPA session. Conclusions: This study is the first objective assessment of the effects of adding OPC to L-DOPA on bradykinesia in patients with PD and motor fluctuations. OPC, in addition to the standard dopaminergic therapy, leads to significant improvements in bradykinesia during clinically relevant periods associated with peripheral L-DOPA dynamics, i.e., the OFF state in the morning, delayed-ON, and wearing-OFF periods. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=176627737
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-023-07233-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 2035
    Subjects:
      – SubjectFull: Parkinson's disease
        Type: general
      – SubjectFull: Dopa
        Type: general
    Titles:
      – TitleFull: Objective assessment of the effects of opicapone in Parkinson's disease through kinematic analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bologna, Matteo
      – PersonEntity:
          Name:
            NameFull: Guerra, Andrea
      – PersonEntity:
          Name:
            NameFull: Colella, Donato
      – PersonEntity:
          Name:
            NameFull: Birreci, Daniele
      – PersonEntity:
          Name:
            NameFull: Costa, Davide
      – PersonEntity:
          Name:
            NameFull: Cannavacciuolo, Antonio
      – PersonEntity:
          Name:
            NameFull: Angelini, Luca
      – PersonEntity:
          Name:
            NameFull: Paparella, Giulia
      – PersonEntity:
          Name:
            NameFull: Antonini, Angelo
      – PersonEntity:
          Name:
            NameFull: Berardelli, Alfredo
      – PersonEntity:
          Name:
            NameFull: Fabbrini, Giovanni
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1